TD Asset Management
AEGR

TD Asset Management’s Aegerion Pharmaceuticals AEGR Stock Holding History

TD Asset Management’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-78,800
Closed -$3.63M – 1332
2014
Q1 		$3.63M Sell
78,800
-2,700
-3% -$158K 0.01% 730
2013
Q4 		$5.78M Buy
81,500
+12,600
+18% +$964K 0.01% 589
2013
Q3 		$5.91M Buy
68,900
+1,000
+1% +$84.8K 0.01% 570
2013
Q2 		$4.3M Buy
+67,900
New +$3.6M 0.01% 617

Other funds holding AEGR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

TD Asset Management's AEGR Position: Q2 2014 in Review

TD Asset Management sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2014, closing a stake of 78,800 shares — an estimated $3.63M sold.

TD Asset Management first reported a position in AEGR in Q2 2013 and held it in 4 quarters. The position peaked at $5.91M in Q3 2013. 129 funds tracked by Wall St. Rank hold AEGR as of Q2 2014.

  • TD Asset Management reported no remaining Aegerion Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • TD Asset Management sold 78,800 Aegerion Pharmaceuticals shares in Q2 2014, an estimated $3.63M.
  • TD Asset Management first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • TD Asset Management's Aegerion Pharmaceuticals position peaked at $5.91M in Q3 2013.
  • 129 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2014.

Based on TD Asset Management's 13F filing for Q2 2014, filed 12 Aug 2014.